CAS NO: | 179068-02-1 |
包装 | 价格(元) |
10mg | 电议 |
50mg | 电议 |
Cas No. | 179068-02-1 |
别名 | N-苯基-7-(羟基亚胺基)环丙烯并[B]苯并吡喃-1A-甲酰胺 |
化学名 | (1aS,7aS,Z)-7-(hydroxyimino)-N-phenyl-1,1a,7,7a-tetrahydrocyclopropa[b]chromene-1a-carboxamide |
Canonical SMILES | O=C([C@]1([C@H]/2C1)OC3=CC=CC=C3C2=N/O)NC4=CC=CC=C4 |
分子式 | C17H14N2O3 |
分子量 | 294.31 |
溶解度 | Soluble in DMSO |
储存条件 | Store at RT |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | PHCCC is a Group I metabotropic glutamate receptor antagonist with EC50 of 6 uM and a positive allosteric modulator of mGluR4. Also as a potent to antagonism for mGluR2 and mGluR8.target: a Group I metabotropic glutamate receptor antagonistEC 50: 6 uMIn vitro: PHCCC potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. In vivo: 1, PHCCC produced antiparkinsonian efficacy in the reserpinized rat model means a significant level of glutamate is available for the activation of the therapeutically relevant mGluR4. 2, The reference for animal administration is 10 mg/kg.(i.p) 3,PHCCC augmentes in vivo genetic and pharmacological models of absence seizures in rats. References: |